讲座信息

讲座信息

您当前的位置: 讲座信息
20190711 Guolian Kang:Post-GWAS Secondary Phenotype Analysis is Cost-Beneficial Only with Valid Analytical Approach
时间:2019-07-07

报告时间:2019年7月11日  14:30-15:30   
报告地点:明德主楼1016会议室
报告题目:Post-GWAS Secondary Phenotype Analysis is Cost-Beneficial Only with Valid Analytical Approach


报告摘要:
Genome-wide association studies (GWAS) have been successful in the last decades to identify common variants associated with common or rare diseases. Study designs most commonly used for GWAS are based on a primary outcome including the case-control study (CC) for studying a common disease or extreme phenotype sequencing design (EPS) for studying an ordinal or continuous phenotype, such as the well-known National Heart, Lung, and Blood Institute Exome Sequencing Project. Besides the primary outcome, extensive data on secondary phenotypes (SP) that may correlate and share the common genetic variants with the primary outcomes are available. Although naïve methods for GWAS could be applied to analyze the secondary phenotypes, they lead to biased risk estimates if there is correlation between the primary outcome and secondary phenotype. This is resulted from the fact that the GWAS samples selected are not a random representative sample of the secondary outcome. Thus, the critical question is how to analyze these secondary outcomes in post-GWAS era? Here, two novel statistical methods for CC (STcc) and EPS (STEPS) designs are proposed. Extensive simulation studies show that the two methods can control false positive rate well and have larger power compared to naïve methods, which is robust to effect pattern of the genetic variant (risk or protective), rare or common variants, and trait distributions). To show their cost-benefit, we also mimicked to re-design two new retrospective studies as in the real practice based on primary outcome of interest, which is same as SP in the EPS study. Application to a genome-wide association study of Benign Ethnic Neutropenia with 7 SPs under an EPS design also demonstrates the striking superiority of the proposed two methods over their alternatives.


报告人简介:
Dr. Kang is currently an Associate Member (=Associate Professor) in Department of Biostatistics at St. Jude Children’s Research Hospital. Her research interests include statistical genetics, system biology, clinical trial design, and genetical epidemiology. She has published more than 80 scientific papers in top-tier journals such Nature Genetics, Journal of Clinical Oncology, The New England Journal of Medicine, etc, which have been cited independently for more than 1,000 times. Several of her methodology research works have been featured by international media such as NewsRX.com (USA), ScienceDaily (USA),International Adaptogens (Venezuela),Nature Review Genetics (UK), and《Transgénicos》(Cuba). Dr. Kang is PI of a Data Coordinating Center funded by NHLBI and lead biostatistician for 9 NCI/NIH funded grants. She has designed more than 50 clinical trial protocols. She is Associate Editor of Frontiers in Genetics and ad hoc reviewers for more than 30 international journals, NIH(USA) and DPFS(UK) grant proposals。